Roche will pay $114.50 per share, more than twice Spark’s closing price on Feb. 22.
The deal will give Roche access to a gene therapy for blindness priced at $850,000 per patient, as well as other projects for hemophilia and neurodegenerative disorders like Huntington’s disease.
Roche’s deal comes as other big-name drugmakers pivot to gene therapy.
Read the full report here.
More articles on pharmacy:
5 recent pharma bankruptcies
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.